Daewoong Pharmaceutical Company Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daewoong Pharmaceutical Company Ltd.
The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
Daewoong Innovation Holdings President Thierry Uh tells Scrip what Korean pharma firms should keep in mind when entering the US market, as well as what R&D and partnering strategies Daewoong has both there and globally.
- Antisense, Oligonucleotides
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.